Rand Abdulrahman

Rand Abdulrahman holds a Doctor of Philosophy from the University of Strathclyde, affiliated with the Strathclyde Institute of Pharmacy and Biomedical Sciences. Their research focuses on lipid nanoparticles, nanoparticle-protein interactions, and analytical methodologies for pharmaceutical applications. Abdulrahman is actively involved in a project funded by AstraZeneca titled 'Novel analytical pipelines for understanding oligonucleotide-loaded lipid nanoparticle critical quality attributes' (2022–2026), serving as a Researcher alongside Principal Investigator Dr. Rattray and Co-investigator Prof. Perrie.

Research interests include lipid biochemistry, nanoparticle engineering, and metrology. Key contributions include developing analytical techniques like frit-inlet asymmetric flow field-flow fractionation to study nanoparticle stability and interactions. Their work aligns with UN Sustainable Development Goals related to health and innovation.

Abdulrahman has presented research at conferences such as the RNA Vaccines and Therapeutics event (2024) and contributed to datasets published via the University of Strathclyde repository, including studies on lipid nanoparticle characterization (2024–2025).